Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

CADL
Candel Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
May 8, 2025 3:59:58 PM EDT
4.75USD+4.626%(+0.21)702,672
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 8, 2025 8:01:30 AM EDT
4.50USD-0.881%(-0.04)1,217
After-hours
May 8, 2025 4:43:30 PM EDT
4.76USD+0.211%(+0.01)10,572
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 5, 2022
08:00AM EST  Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at the following virtual investor conferences in January:   GlobeNewswire Inc
Dec 15, 2021
05:46AM EST  Bionaut Labs, Candel To Work On Development Of Microscale Robots To Deliver Oncolytic Viral Immunotherapies   RTTNews
05:00AM EST  -- Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain tumors   GlobeNewswire Inc
Dec 10, 2021
08:03AM EST  Candel Therapeutics Announces Collaboration With Partnership For Accelerating Cancer Therapies And The Cancer Immune Monitoring And Analysis Centers Cancer Immunologic Data Commons For Lung Cancer Trial For CAN-2409   Benzinga
08:00AM EST  Candel Therapeutics and Partnership for Accelerating Cancer   GlobeNewswire Inc
Nov 19, 2021
10:09AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021   Benzinga
08:20AM EST  The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial   Benzinga
05:40AM EST  BMO Capital Initiates Coverage On Candel Therapeutics with Outperform Rating, Announces Price Target of $18   Benzinga
Nov 15, 2021
10:37AM EST  The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More   Benzinga
Nov 12, 2021
09:16AM EST  UPDATE: Candel Therapeutics Q3 Adj. EPS $(0.26) Down From $(0.22) YoY, Sales $31.00K, Same YoY   Benzinga
08:18AM EST  Candel Therapeutics, Cue, Madrigal Pharma, F-star, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting   Benzinga
08:18AM EST  Candel Therapeutics Q3 EPS $(0.69) Down From $(0.22) YoY, Sales $31.00K, Same YoY   Benzinga
08:14AM EST  Candel Therapeutics, Cue, Madrigal Pharma, Aligos, Albireo Pharma, Actinium Highlights Presentations At Society For Immunotherapy Of Cancers Meeting Nov. 12-14, The Liver Meeting   Benzinga
08:00AM EST  Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.   GlobeNewswire Inc
08:00AM EST  -- Data presented at the Society for Immunotherapy of Cancers (SITC) 36thAnnual Meeting -- Intra-tumoral administration of CAN-3110 elicited significant T-cell infiltration and expansion of T-cell repertoire in patients with recurrent high-grade glioma   GlobeNewswire Inc
Nov 2, 2021
08:00AM EDT  Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November:   GlobeNewswire Inc
Nov 1, 2021
08:00AM EDT  Candel Therapeutics Announces Upcoming Data Presentations on its   GlobeNewswire Inc
Oct 28, 2021
08:00AM EDT  Candel Therapeutics, Inc.(Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announcedthatdata onpatient-reportedtolerabilityassessmentof intraprostatic injectionswill bepresentedin a virtual poster sessionat the28thAnnualProstate Cancer FoundationScientific Retreat.   GlobeNewswire Inc
Oct 19, 2021
08:00AM EDT  Candel TherapeuticsAppoints Mace L. Rothenberg,   GlobeNewswire Inc
Oct 4, 2021
08:08AM EDT  Candel Therapeutics Announces Participation In Upcoming Society For Immunotherapy Of Cancer's (SITC) 36th Annual Meeting   Benzinga
08:00AM EDT  Candel Therapeutics Announces Participation in Upcoming Society   GlobeNewswire Inc
Oct 1, 2021
08:00AM EDT  Candel Therapeutics Announces Participation in Upcoming Scientific   GlobeNewswire Inc
Sep 9, 2021
08:26AM EDT  Candel Therapeutics Announces Presentations Of Key Clinical Data At AdMeTech And European Association Of Neuro-Oncology Conferences In September 2021   Benzinga
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
08:00AM EDT  Candel Therapeutics Announces Presentations of Key Clinical Data   GlobeNewswire Inc
Sep 8, 2021
02:32PM EDT  Mid-Afternoon Market Update: Kadmon Surges Following Acquisition News; UiPath Shares Drop   Benzinga
02:29PM EDT  Mid-Day Market Update: Crude Oil Rises 1%; REV Group Shares Plummet   Benzinga
08:25AM EDT  Candel Therapeutics Q2 EPS $(1.46)   Benzinga
08:00AM EDT  Candel Therapeutics, Inc. (the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.   GlobeNewswire Inc
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 7, 2021
08:06AM EDT  Candel Therapeutics Completes Enrollment In Phase 3 Clinical Trial Of CAN-2409 In Combination With Valacyclovir For The Treatment Of Intermediate-High Risk Localized Prostate Cancer   Benzinga
08:00AM EDT  Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial   GlobeNewswire Inc
Aug 23, 2021
10:32AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021   Benzinga
09:46AM EDT  UBS Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $9   Benzinga
08:48AM EDT  Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22   Benzinga
05:35AM EDT  Credit Suisse Initiates Coverage On Candel Therapeutics with Outperform Rating, Announces Price Target of $15   Benzinga
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:00AM EDT  Candel Therapeutics Announces Closing of Initial Public Offering,   GlobeNewswire Inc
Aug 15, 2021
12:16PM EDT  The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
11:06AM EDT  The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Jul 30, 2021
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
Jul 29, 2021
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 27, 2021
11:15AM EDT  Candel Therapeutics Shares Open For Trade At $8; IPO Priced $8/Share   Benzinga
11:13AM EDT  The IPO Market Is On Fire With Another Record Week Ahead   Benzinga
11:13AM EDT  Candel Therapeutics Shares Will Open For Quote At 11 a.m. EDT, Expected To Open For Trade After 11:10 a.m. EDT; IPO Priced $8/Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC